Vera Therapeutics, Inc. (VERA) stock
VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
$25.58−0.62 (-2.37%)
Close on Nov 18, 2026Market cap $1.84BP/E –Yield –
Vera Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vera Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$338.91M. For fiscal 2025 it was -$241.73M. The highest annual figure on record is -$23.71M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$241.73M | – |
| FY2024 | Dec 31, 2024 | -$135.65M | – |
| FY2023 | Dec 31, 2023 | -$92.24M | – |
| FY2022 | Dec 31, 2022 | -$67.66M | – |
| FY2021 | Dec 31, 2021 | -$23.71M | – |
| FY2020 | Dec 31, 2020 | -$34.91M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$100.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$106.52M | – |
| Q4 FY2025 | Dec 31, 2025 | -$70.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -$62.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$55.01M | – |
| Q1 FY2025 | Mar 31, 2025 | -$54.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.83M | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.87M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.77M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.46M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.04M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.00M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.48M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.67M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.12M | – |
| Q4 FY2020 | Dec 31, 2020 | -$27.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.72M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.36M | – |
See a number that looks wrong?